Comparative Pharmacology
Head-to-head clinical analysis: LYUMJEV versus PRANDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYUMJEV versus PRANDIN.
LYUMJEV vs PRANDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LYUMJEV (insulin lispro-aabc) is a rapid-acting insulin analog that binds to the insulin receptor (IR), activating the IR tyrosine kinase cascade. This leads to increased glucose uptake in peripheral tissues (primarily skeletal muscle and adipose tissue), inhibition of hepatic gluconeogenesis, and promotion of glycogen synthesis. The aabc amino acid substitution (insulin lispro with proline at B28 replaced by lysine and lysine at B29 replaced by proline, plus an additional modification) results in faster dissociation from the insulin receptor and accelerated absorption from subcutaneous tissue compared to regular human insulin.
Repaglinide stimulates insulin secretion from pancreatic beta cells by binding to and closing ATP-sensitive potassium channels, leading to membrane depolarization and calcium influx.
Subcutaneous injection at mealtime (within 15 minutes before or immediately after meal). Doses individualized; typical range 0.2-1.0 units/kg/day.
0.5–4 mg orally 0–30 minutes before meals, typically 2–4 times daily. Maximum single dose: 4 mg. Maximum total daily dose: 16 mg.
None Documented
None Documented
Terminal elimination half-life of LYUMJEV (insulin lispro) is approximately 13.7 minutes (0.23 hours) in healthy subjects, reflecting rapid clearance from the bloodstream.
Terminal elimination half-life: 1.0-1.5 hours. Clinically, due to rapid elimination, repaglinide requires dosing before each meal to control postprandial glucose.
Primarily renal; approximately 90% of absorbed dose is excreted via urine as metabolites and unchanged drug, with the remainder eliminated in feces (<10%).
Primarily hepatic metabolism via CYP2C8 and CYP3A4; metabolites excreted in bile (90%) and urine (10%). Less than 0.1% excreted unchanged in urine.
Category C
Category C
Antidiabetic
Antidiabetic